Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3911254 | 0.85 | KCNA3 (0.49) | KCNA3ALDH1A1MAOBMCL1TSHR | |
| SCHEMBL3920121 | 0.84 | KCNA3 (0.51) | KCNA3ALDH1A1MAOBTSHR | |
| SCHEMBL3915228 | 0.84 | KCNA3 (0.47) | KCNA3ALDH1A1MAOBTSHR | |
| SCHEMBL3914736 | 0.83 | KCNA3 (0.50) | KCNA3ALDH1A1MAOBTSHR | |
| SCHEMBL3913362 | 0.82 | KCNA3 (0.42) | KCNA3ALDH1A1KDM4EHPGDHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL3913356 | 0.81 | HTR2C (0.45) | KCNA3ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3922173 | 0.81 | GFER (0.49) | KCNA3MEN1KMT2AMAPTALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3923252 | 0.80 | KCNA3 (0.46) | KCNA3ALDH1A1MAOBMCL1 | |
| Trifluoroacetic Acid SCHEMBL5728404 | 0.80 | HTR2C (0.44) | KCNA3ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3913361 | 0.80 | ALDH1A1 (0.47) | KCNA3ALDH1A1KDM4EMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667988-B1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMA INC (US) | 2013-04-10 | — | — | EP | claimed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | claimed |
| EP-1667988-B1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMA INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054681-A1 | Coumarins as iNOS inhibitors | NOS2, NOS1, NOS3 | KCNA3 3807/4885MEN1 3661/4885KMT2A 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.